Results show that tumours from patients with the SNP combination rs22(GC)+rs30(AG) had significantly more CD163+ Mɸ (median 2.28–2.56 fold) compared to rs22(GC)+rs29(TC) and rs22(CC) (Figure 3b and Table S3). Here, CD163 is linked to neoplasm.